Please assess the completion status of the following clinical trial:

Trial Title: Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with STEMI defined as both of the following: a) Symptoms of myocardial ischemia lasting for ≥ 30 minutes, and b) Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads.~* Referred for primary PCI for presenting symptoms.~* Randomized within 12 hours of symptom onset and prior to diagnostic angiography.~Exclusion Criteria:~* Age ≤18 years.~* Pregnancy or breastfeeding.~* Current or planned treatment with a PCSK9 inhibitor.~* Allergy or contra-indication to a PCSK9 inhibitor.~* Killip class ≥2.~* Known Creatinine clearance \<30mL/min.~* Suspected takotsubo / stress-induced cardiomyopathy or acute pericarditis.~* Any other medical, geographic, or social factor making study participation impractical or precluding follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alirocumab (Type: EXPERIMENTAL): None
- Sham Control (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).